Advertisement

Lung

, Volume 195, Issue 6, pp 775–779 | Cite as

Prognosis of Cancer with Synchronous or Metachronous Malignant Pleural Effusion

  • José M. PorcelEmail author
  • Cristina Solé
  • Antonieta Salud
  • Silvia Bielsa
Article

Abstract

Purpose

Malignant pleural effusions (MPE) may either coincide with or follow the diagnosis of a primary tumor. Whether this circumstance influences prognosis has not been well substantiated.

Methods

Retrospective review of all consecutive patients who were cared for at a Spanish university hospital during an 11-year period and received a diagnosis of MPE.

Results

Of 401 patients, the MPE was the first evidence of cancer in 265 (66%), and it followed a previously diagnosed neoplasm in 136 (34%). Lung cancer predominated in the former group (131, 50%), and breast cancer in the latter (55, 40%). MPE that were the presenting manifestation of hematological and ovarian tumors had a statistically significant survival advantage as compared to those which developed in patients from a previously known cancer (respective absolute differences of 41 and 20 months; p < 0.005).

Conclusions

In hematological and ovarian malignancies, the synchronous or metachronous diagnosis of MPE may have prognostic implications.

Keywords

Malignant pleural effusion Lung cancer Breast cancer Ovarian cancer Lymphoma Survival Pleural procedures 

Notes

Compliance with Ethical Standards

Conflict of interest

There are no conflicts of interest with the current study.

Ethical Approval

All studies performed in human participants were in accordance with the ethical standards of the institutional research committee and with the Helsinki declaration.

References

  1. 1.
    Porcel JM, Esquerda A, Vives M, Bielsa S (2014) Etiology of pleural effusions: analysis of more than 3000 consecutive thoracenteses. Arch Bronconeumol 50(5):161–165CrossRefPubMedGoogle Scholar
  2. 2.
    Porcel JM, Gasol A, Bielsa S, Civit C, Light RW, Salud A (2015) Clinical features and survival of lung cancer patients with pleural effusions. Respirology 20(4):654–659CrossRefPubMedGoogle Scholar
  3. 3.
    Light RW (2013) Pleural diseases, 6th edn. Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar
  4. 4.
    Monte SA, Ehya H, Lang WR (1987) Positive effusion cytology as the initial presentation of malignancy. Acta Cytol 31(4):448–452PubMedGoogle Scholar
  5. 5.
    van de Molengraft FJ, Vooijs GP (1988) The interval between the diagnosis of malignancy and the development of effusions, with reference to the role of cytologic diagnosis. Acta Cytol 32(2):183–187PubMedGoogle Scholar
  6. 6.
    Cellerin L, Marcq M, Sagan C, Chailleux E (2008) Pleurésies malignes révélatrices d’un cancer: comparaison des étiologies avec les pleurésies métastatiques d’un cancer connu. Rev Mal Respir 25(9):1104–1109CrossRefPubMedGoogle Scholar
  7. 7.
    Fysh ET, Bielsa S, Budgeon CA, Read CA, Porcel JM, Maskell NA, Lee YC (2015) Predictors of clinical use of pleurodesis and/or indwelling pleural catheter therapy for malignant pleural effusion. Chest 147(6):1629–1634CrossRefPubMedGoogle Scholar
  8. 8.
    Clive AO, Kahan BC, Hooper CE, Bhatnagar R, Morley AJ, Zahan-Evans N, Bintcliffe OJ, Boshuizen RC, Fysh ET, Tobin CL, Medford AR, Harvey JE, van den Heuvel MM, Lee YC, Maskell NA (2014) Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax 69(12):1098–1104CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Porcel JM, Quirós M, Gatius S, Bielsa S (2017) Examination of cytological smears and cell blocks of pleural fluid: complementary diagnostic value for malignant effusions. Rev Clin Esp 217(3):144–148CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • José M. Porcel
    • 1
    • 2
    Email author
  • Cristina Solé
    • 1
  • Antonieta Salud
    • 2
    • 3
  • Silvia Bielsa
    • 1
    • 2
  1. 1.Pleural Medicine Unit, Department of Internal MedicineArnau de Vilanova University HospitalLleidaSpain
  2. 2.Institute for Biomedical Research Dr Pifarre Foundation, IRBLLEIDALleidaSpain
  3. 3.Department of Medical OncologyArnau de Vilanova University HospitalLleidaSpain

Personalised recommendations